Press Releases / Notices

The company’s press releases sometimes carry information on pharmaceutical drugs and products in the pipeline. Under no circumstances is such information provided to promote or advertise these products or offer medical advice.

NEWS 2011

June 01, 2011 Pharmaceuticals

Launch of an agent to treat Acute Promyelocytic Leukemia (APL) in Korea

KYOTO, JAPAN – (June 1, 2011) – Nippon Shinyaku Co., Ltd (Headquarters: Kyoto, Japan; President: Shigenobu Maekawa) today announced that BL&H Co., Ltd. (Headquarters: Seoul, Korea; President: Dong Chul Roh), a licensee of Nippon Shinyaku was notified of the reimbursement price of TRISENOX® Injection and has launched the product in Korea. TRISENOX® injection is indicated, in Korea, for induction of remission and consolidation in adult patients with relapsed/refractory APL.

TRISENOX® Injection is marketed in more than 10 countries in the USA and Europe. Nippon Shinyaku was licensed for TRISENOX® Injection from Cephalon, Inc. (Headquarters: Pennsylvania, USA.; CEO: Kevin Buchi) in December 2002 and launched the product in Japan in December 2004.
Nippon Shinyaku concluded the license agreement for TRISENOX® Injection with BL&H in November 2008, and the product was approved as an orphan drug in Korea in June 2010.

APL is a subtype of acute myeloid leukemia and the occurrence number of APL patients is presumed to be 500 to 700 in Japan, and around 250 in Korea annually.
TRISENOX® injection had high rates of complete remission for APL patients whose disease did not respond to initial treatment or relapsed. The safety and efficacy of TRISENOX® Injection was proved and the launch of the product will contribute to the treatment of relapsed or refractory APL patients also in Korea.

(Reference)
Company profile of BL&H
   Corporate Name: BL&H Co., Ltd.
   Established: October, 1999
   President & CEO: Dong Chul Roh
   Address: 9F, Dealim Office Valley, 97-3 Guro4-Dong, Guro-ku, Seoul,
   Korea
   Number of Employees: 40
   Sales: 9,698 million KRW (in 2010)
   Business line: Development and sales of pharmaceuticals